1431 related articles for article (PubMed ID: 33958794)
1. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.
Bassez A; Vos H; Van Dyck L; Floris G; Arijs I; Desmedt C; Boeckx B; Vanden Bempt M; Nevelsteen I; Lambein K; Punie K; Neven P; Garg AD; Wildiers H; Qian J; Smeets A; Lambrechts D
Nat Med; 2021 May; 27(5):820-832. PubMed ID: 33958794
[TBL] [Abstract][Full Text] [Related]
2. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
3. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD
Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832
[TBL] [Abstract][Full Text] [Related]
4. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
Graeser M; Feuerhake F; Gluz O; Volk V; Hauptmann M; Jozwiak K; Christgen M; Kuemmel S; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kolberg-Liedtke C; Kates R; Wuerstlein R; Nitz U; Kreipe HH; Harbeck N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963012
[TBL] [Abstract][Full Text] [Related]
5. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.
Hammerl D; Martens JWM; Timmermans M; Smid M; Trapman-Jansen AM; Foekens R; Isaeva OI; Voorwerk L; Balcioglu HE; Wijers R; Nederlof I; Salgado R; Horlings H; Kok M; Debets R
Nat Commun; 2021 Sep; 12(1):5668. PubMed ID: 34580291
[TBL] [Abstract][Full Text] [Related]
6. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.
Kaptein P; Jacoberger-Foissac C; Dimitriadis P; Voabil P; de Bruijn M; Brokamp S; Reijers I; Versluis J; Nallan G; Triscott H; McDonald E; Tay J; Long GV; Blank CU; Thommen DS; Teng MWL
Sci Transl Med; 2022 Apr; 14(642):eabj9779. PubMed ID: 35476594
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
8. CD28/PD1 co-expression: dual impact on CD8
Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral CD4
Oh DY; Kwek SS; Raju SS; Li T; McCarthy E; Chow E; Aran D; Ilano A; Pai CS; Rancan C; Allaire K; Burra A; Sun Y; Spitzer MH; Mangul S; Porten S; Meng MV; Friedlander TW; Ye CJ; Fong L
Cell; 2020 Jun; 181(7):1612-1625.e13. PubMed ID: 32497499
[TBL] [Abstract][Full Text] [Related]
10. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
Liu Y; Guo X; Zhan L; Wang L; Wang X; Jiang M
Comput Math Methods Med; 2021; 2021():4468140. PubMed ID: 34422089
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral dendritic cell-CD4
Magen A; Hamon P; Fiaschi N; Soong BY; Park MD; Mattiuz R; Humblin E; Troncoso L; D'souza D; Dawson T; Kim J; Hamel S; Buckup M; Chang C; Tabachnikova A; Schwartz H; Malissen N; Lavin Y; Soares-Schanoski A; Giotti B; Hegde S; Ioannou G; Gonzalez-Kozlova E; Hennequin C; Le Berichel J; Zhao Z; Ward SC; Fiel I; Kou B; Dobosz M; Li L; Adler C; Ni M; Wei Y; Wang W; Atwal GS; Kundu K; Cygan KJ; Tsankov AM; Rahman A; Price C; Fernandez N; He J; Gupta NT; Kim-Schulze S; Gnjatic S; Kenigsberg E; Deering RP; Schwartz M; Marron TU; Thurston G; Kamphorst AO; Merad M
Nat Med; 2023 Jun; 29(6):1389-1399. PubMed ID: 37322116
[TBL] [Abstract][Full Text] [Related]
12. Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1
Liang H; Li H; Xie Z; Jin T; Chen Y; Lv Z; Tan X; Li J; Han G; He W; Qiu N; Jiang M; Zhou J; Xia H; Zhan Y; Cui L; Guo W; Huang J; Zhang X; Wu YL
Thorac Cancer; 2020 Oct; 11(10):2941-2954. PubMed ID: 32894006
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
14. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
15. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
[TBL] [Abstract][Full Text] [Related]
16. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
17. Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer.
Saito S; Kono M; Nguyen HCB; Egloff AM; Messier C; Lizotte P; Paweletz C; Adkins D; Uppaluri R
Clin Cancer Res; 2024 May; 30(9):1934-1944. PubMed ID: 38372707
[TBL] [Abstract][Full Text] [Related]
18. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
19. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.
Lee AH; Sun L; Mochizuki AY; Reynoso JG; Orpilla J; Chow F; Kienzler JC; Everson RG; Nathanson DA; Bensinger SJ; Liau LM; Cloughesy T; Hugo W; Prins RM
Nat Commun; 2021 Nov; 12(1):6938. PubMed ID: 34836966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]